-

Thermo Fisher Scientific Releases 2023 Corporate Social Responsibility Report

Report highlights company’s commitments to all of its stakeholders and society

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its 2023 Corporate Social Responsibility (CSR) report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues.

“Thermo Fisher is driven by a profound Mission – to enable our customers to make the world healthier, cleaner, and safer,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We also understand our obligation goes beyond enabling our customers’ success and extends to making the world a better place by supporting our communities, being a good steward of our planet and creating a great work environment for our colleagues. I am proud of what we’ve accomplished so far and deeply grateful to our global team for their passion for fulfilling our Mission and delivering on our commitments to society.”

Highlights of the report include:

Communities

  • Collectively volunteered more than 100,000 hours to support communities around the world.
  • Reached more than 60,000 students through the Thermo Fisher Scientific Junior Innovators Challenge in partnership with the Society for Science, the premier STEM competition for middle schoolers in the U.S.
  • Established collaborations with the National Quality Minority Forum, to increase diversity in clinical trials, and Project HOPE, to advance health equity among HIV-positive youth in sub-Saharan Africa.

Environment

  • Achieved key milestones toward the company’s goal of net-zero emissions by 2050, including the sourcing 41% of global electricity from renewable energy.
  • Announced a new agreement to power over half of Thermo Fisher’s European footprint with 100% renewable energy by 2025.
  • Established new commitment to achieve 80% renewable electricity utilization globally by 2030.

Colleagues

  • Advanced our vibrant and inclusive culture where colleagues’ unique backgrounds and perspectives are embraced.
  • Continued to develop the workforce, including launching new training programs for emerging technologies and an internal generative AI platform.
  • Enhanced global access to wellness resources.

In reporting its CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks, including the Global Reporting Initiative (GRI) Standards, the IFRS Foundation’s SASB Standards, the Task Force on Climate-related Financial Disclosures (TCFD) and the United Nations Sustainable Development Goals (SDGs). Thermo Fisher makes additional topic-specific ESG data available to key stakeholders through its annual CDP report and voluntary disclosure of EEO-1 information.

Learn more at www.thermofisher.com/CSR.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Sandy Pound
Thermo Fisher Scientific
781-622-1223
sandy.pound@thermofisher.com

Investors:
Rafael Tejada
Thermo Fisher Scientific
781-622-1356
rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Sandy Pound
Thermo Fisher Scientific
781-622-1223
sandy.pound@thermofisher.com

Investors:
Rafael Tejada
Thermo Fisher Scientific
781-622-1356
rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom